AMRX: Amneal Pharmaceuticals Inc - Class A

AMRX新闻

• 14:57 AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
• 13:42 BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
• 16:29 JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
• 16:10 SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
• 15:07 RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
• 14:09 Here's Why You Should Add ACET Stock to Your Portfolio Now
• 14:04 Acadia Gets European Commission Nod for Daybu in Rett Syndrome
• 13:40 Are Medical Stocks Lagging Bioventus (BVS) This Year?
• 15:39 Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
• 16:40 TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
• 14:56 Reasons Why Investors Should Consider Betting on PGEN Stock
• 14:16 RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
• 12:46 4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
• 16:18 AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• 15:33 Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
• 07:21 Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar
• 16:01 ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
• 14:36 UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
• 14:33 EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
• 12:32 5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
• 15:02 Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
• 14:14 Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
• 13:43 CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
• 16:14 ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus